The FDA revoked the emergency use authorization for Chloroquine and Hydroxychloroquineare, except in the context of a clinical trial. Recommendations are against the use of lopinavir/ritonavir or other HIV protease inhibitors; unfavorable pharmacodynamics and clinical trials have not demonstrated a clinical benefit. The use of tocilizumab in combination with dexamethasone is recommended in certain hospitalized patients. Donor plasma may contain antibodies that may help suppress the virus and modify the inflammatory response. The FDA has issued an Emergency Use Authorization for convalescent plasma. Low-titer convalescent plasma is no longer authorized through the convalescent plasma EUA.
SNOMED_CT Problem=191415002 (PB0050); SNOMED_CT Cat-Tar=409022004 (CG0003, TG0073)
